C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection
Authors:
- 1 June 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (6) , 1151-1155
Abstract
Background Complement fixation by donor-specific HLA antibodies (DSA) is a primary mechanism for antibody-mediated damage of organ allografts. Using a recently developed kit that measures C1q binding to distinguish complement fixing and nonfixing antibodies, studies showed that C1q + DSAs have a higher risk of rejection and graft loss compared to C1q-DSA. The objective of this study was to assess the ability of the C1q-binding assay to identify clinically significant de novo DSA in renal transplant recipients and to define the properties of DSA that confer C1q binding ability. Methods The DSA-positive sera from 34 kidney recipients, 19 with biopsy-proven antibody-mediated rejection (AMR) + and 15 who were AMR−, were assayed in C1q-binding assays (C1q Screen; One Lambda, Inc. Canoga Park, CA). The correlation between C1q-binding activity, presence of AMR, DSA mean fluorescence intensity (MFI) values, and immunoglobulin G isotype was determined. Results Fifty-three percent (10/19) of sera from AMR+ patients had C1q + DSA, whereas only 13% (2/15) of sera from AMR− patients contained C1q + DSA. C1q + DSA exhibited significantly higher MFI values regardless of whether they were from AMR+ or AMR− patients (16,118 ± 6698 vs 6429 ± 4003; P < 0.0001). C1q + DSA converted to C1q − when diluted to a comparable MFI level as the C1q − DSA from AMR− patients, and some C1q − antibodies converted to C1q + when concentrated to MFI levels comparable to those observed for AMR+/C1q + sera. Conclusions The C1q binding activity by de novo DSA in patients with AMR largely reflects differences in antibody strength. The C1q assay does not appear to distinguish functionally distinct DSA with clinical significance.Keywords
This publication has 17 references indexed in Scilit:
- Complement-Binding Anti-HLA Antibodies and Kidney-Allograft SurvivalNew England Journal of Medicine, 2013
- Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in TransplantationTransplantation, 2013
- Complement‐fixing donor‐specific antibodies identified by a novel C1q assay are associated with allograft lossPediatric Transplantation, 2011
- Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beadsHuman Immunology, 2011
- Luminex-Based Desensitization Protocols: The University of Wisconsin Initial ExperienceTransplantation, 2011
- Complement (C1q) fixing solid‐phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patientsTransfusion, 2011
- C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney TransplantationTransplantation, 2011
- Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patientsThe Journal of Heart and Lung Transplantation, 2011
- Pretransplant Donor-Specific Antibodies Detected by Single-Antigen Bead Flow Cytometry Are Associated With Inferior Kidney Transplant OutcomesTransplantation, 2010
- Baseline Donor‐Specific Antibody Levels and Outcomes in Positive Crossmatch Kidney TransplantationAmerican Journal of Transplantation, 2010